ANTIBIOTIKLARGA CHIDAMLILIK: KELIB CHIQISHI, MEXANIZMLARI VA OLDINI OLISH STRATEGIYALARI.

Authors
  • Gulmurotova Dilafruz Shoymardonovna

    Toshkent davlat tibbiyot universiteti, Mikrobiologiya virusologiya va immunologiya kafedrasi assistenti

    Author

  • Jalolova Malika Baxrom qizi

    Toshkent davlat tibbiyot universiteti 1-son davolash fakulteti 218-guruh talabasi

    Author

  • Nosirjonova Muslimaxon Isroiljon qizi

    Toshkent davlat tibbiyot universiteti 1-son davolash fakulteti 218-guruh talabasi

    Author

Keywords:
Array
Abstract

Ushbu maqolada antibiotiklarga chidamlilik (Antimicrobial resistance, AMR) muammosining dolzarbligi, kelib chiqish omillari, rivojlanish mexanizmlari va uni oldini olish strategiyalari tahlil qilinadi. Antibiotiklardan noto‘g‘ri va ortiqcha foydalanish, shuningdek qishloq xo‘jaligida keng qo‘llanilishi mikroorganizmlarda chidamlilikning rivojlanishiga asosiy sabab bo‘layotgani ko‘rsatib o‘tilgan.

Maqolada bakteriyalarning antibiotiklarga chidamlilik hosil qilish mexanizmlari, jumladan fermentativ inaktivatsiya, genetik o‘zgarishlar, effluks pompalar va biofilm hosil qilish jarayonlari yoritilgan. Shuningdek, antibiotiklarga chidamlilikni aniqlashdagi diagnostik muammolar, turli davlatlarda qo‘llaniladigan chegaraviy ko‘rsatkichlarning turli mamlakatlarda farqlanishi va epidemiologik kuzatuv tizimlarining yetarli darajada mukammal emasligi tahlil qilingan.Bundan tashqari, maqolada antibiotiklarga chidamlilikning klinik ahamiyati real misollar asosida ko‘rib chiqilgan hamda zamonaviy yondashuvlar, xususan antibiotiklardan oqilona foydalanish (antibiotic stewardship), yangi dori vositalari ishlab chiqish va alternativ davolash usullari haqida ma’lumot berilgan.

Xulosa sifatida antibiotiklarga chidamlilik ko‘p omilli global muammo ekanligi va uni samarali nazorat qilish uchun kompleks yondashuv zarurligi ta’kidlangan.

References

1.World Health Organization. (1997). Antimicrobial Resistance Monitoring Programme. WHO Drug Information 11, 248–9 https://apps.who.int/iris/handle/10665/54019 .

2.Lennox, A., Phillips, L., Monnet, D., McGowan, J. E., Tenover, F.& Gaynes, R. (1997). Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clinical Infectious Diseases 24, 211–5 https://doi.org/10.1093/clinids/24.2.211 .

3.House of Lords Select Committee on Science and Technology (1998). Resistance to antibiotics and other antimicrobial agents. https://publications.parliament.uk/pa/ld199798/ldselect/ldsctech/081v/08101.htm

4.Wiedemann, B. (1996). Epidemiology, control and treatment of multiresistant Gram-negative rods. Drugs 52, Suppl. 2, 95–100 https://publications.parliament.uk/pa/ld199798/ldselect/ldsctech/081v/08101.htm .

5.Laurichesse, H., Grimaud, O., Waight, P., Johnson, A. P.,George, R. C. & Miller, E. (1998). Pneumococcal bacteraemia andmeningitis in England and Wales, 1993 to 1995. Communicable Disease and Public Health 1, 22–7 https://pubmed.ncbi.nlm.nih.gov/9624767 /⁠ .

6.Caputo, G. M., Appelbaum, P. C. & Liu, H. H. (1993). Infections due to penicillin-resistant pneumococci. Clinical, epidemiologic, and microbiologic features. Archives of Internal Medicine 153, 1301–10 https://doi.org/10.1001/archinte.1993.00410130069009 .

7.Pallares, R., Linares, J., Vadillo, M., Cabellos, C., Manresa, F., Viladrich, P. F. et al. (1995). Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. New England Journal of Medicine 333, 474–80 https://doi.org/10.1056/NEJM199508173330702 .

8.Jacobs, R. F., Kaplan, S. L., Schutze, G. E., Dajani, A. S., Leggiadro, R. J., Rim, C. S. et al. (1996). Relationship of MICs to efficacy of cefotaxime in treatment of Streptococcus pneumoniae infections. Antimicrobial Agents and Chemotherapy 40, 895–8 https://doi.org/10.1128/AAC.40.4.895

9.Finch, R. G. (1997). In-vitro antimicrobial susceptibility testing: does it really matter? Journal of Chemotherapy 9, Suppl. 1, 3–6 https://doi.org/10.1179/joc.1997.9.Supplement-1.3 .

10.Voss, A. (1996). Staphylococcus aureus. Pan-European antibiotic resistance and infection control. Chemotherapie Journal 5, 5–6 https://pubmed.ncbi.nlm.nih.gov/9156875/ .

11.Ayliffe, G. A. J. (1997). The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus. Clinical Infectious Diseases 24, Suppl. 1, S74–9 https://doi.org/10.1093/clinids/24.Supplement_1.S74 .

12.Baquero, F. and the Task Force of the General Direction for Primary Health Planning of the Spanish Ministry of Health. (1996). Antibiotic resistance in Spain: what can be done? Clinical Infectious Diseases 23, 819–26 https://doi.org/10.1093/clinids/23.4.819 .

13.Hastings, A., French, D. & McKinley, R. (1996). The development of a general practice formulary of drugs for out-of-hours care. Pharmaceutical Journal 256, 900–2 https://pharmaceutical-journal.com/article/ld/general-practice-formulary .

14.Courvalin P. Antimicrobial drug resistance: prediction is very difficult, especially about the future. Emerg.Inf. Dis.2005; 11(10) https://doi.org/10.3201/eid1110.050405 .

15.Hegstad K, Mikalsen T, Coque TM, Werner G, Sundsfjord A. Mobile genetic elements and their contribution to the emergence of antimicrobial resistant Enterococcusfaecalisand Enterococcus faecium. Clin.Microbiol.infec. 2010; 16(6): 541-554 https://doi.org/10.1111/j.1469-0691.2010.03226 .

16.Rafaillidis PI, Pitsomunis AI and Falagas ME. Meta analyses on the optimization of the duration of antimicrobial treatment for various infections. Infect. Dis. Clin. North Am. 2009; 23: 269-276 https://doi.org/10.1016/j.idc.2009.02.005 .

17.Gordon MA and Banda HT. Non-typhoidalbacteraemia among HIVinfected Malawian adults: High mortality and frequent recrudescence. AIDS.2002; 16: 1633-1641 https://doi.org/10.1097/00002030-200208160-00011 .

18.Iwe P. Textbook of Pharmacology.AfrFirPubLtd, Onitsha, Nig, 2006; 480-49 https://www.worldcat.org/title/textbook-of-pharmacology/ .

19.Silbergeld E, Graham J and Price L. Industrial food animal production, antimicrobial resistance, and human health.Ann. Rev Pub Health,2008; 29: 151–169 https://doi.org/10.1146/annurev.publhealth.29.020907.090904 .

20.Moran GJ, Amii RN, Abrahamian FM and Talan D A. Methicillin resistant Staphylococcus aureusin community acquired skin infection. Emerg.Inf. Dis. 2005; 11: 928-930 https://doi.org/10.3201/eid1106.040641 .

21.KieningerAN andLipsett PA. Hospital acquired pneumonia: pathophysiology, diagnosis and treatment. Surg. Clin. North. Am.,2009; 89: 439-461 https://doi.org/10.1016/j.suc.2009.03.001 .

22.Clewell D. B. Antibiotic resistance plasmids in bacteria.In Wiley Online Library.Retrieved from http://www.els.net/WileyCDA/ElsArticle/refId-a0001491.html .2014

23.Joint Expert Technical Advisory Committee on Antibiotic Resistance (JETACAR).The use of antibiotics in food-producing animals. Report of the Joint Expert Technical Advisory Committee on Antibiotic Resistance (JETACAR).Canberra, Austr. 1999; Pp 20 https://www.health.gov.au/resources/publications/jetacar .

24.Fluit AC, Visser MR and Schmitz FJ. Molecular detection of antimicrobial resistance. Clin.Microbiol.Rev.2001; 14: 836–871 https://doi.org/10.1128/CMR.14.4.836-871.2001 .

25.Sageman A. Antibiotic Resistance Mechanisms, Problems, and Solutions" (2015).Honors Projects. Paper 416 https://scholarworks.gvsu.edu/honorsprojects/416/

26.Holcomb HG, Durbin, KJ, Choi KJ, Darling ND an Angerio A D. Methicillin resistant Staphylococcusaureus as a threat to public health: A cellular approach.Journal of Health Sciences, GeorgiaUniversity, 2008 https://pubmed.ncbi.nlm.nih.gov (qidirish orqali: “MRSA cellular approach”) Prescott Microbiology .

27.Willey J, Sherwood L, Wolver ton C. Prescott Microbiology. 9th Edition, McGraw-Hill, New Yk.,2013; 13: 377-400.v

Cover Image
Downloads
Published
2026-05-05
Section
Articles